I was able to take SESL on a public spin at the Bio-ITWorld meeting last week in Hannover, and it was very well received. As we at the Pistoia Alliance bring this project to a close, it’s clear that we’re in a SESL-is-dead, long-live-SESL situation as we determine the best way to leverage the lessons from this project in other initiatives—very likely the Open PHACTS project sponsored by the IMI.
I first used the phrase “information ecosystem” to describe the biopharma informatics environment at the Pistoia Alliance Annual Face-to-Face board meeting last February. It’s a simple concept that’s widely understood now.
Let me say up front that we firmly believe as Barry does: That it’s through the ability to share key information services and facilitate effective collaboration that we ALL will increase our chances of successfully innovating. That’s what is going to bring success to our industry and to the future lives of patients everywhere.
A few weeks ago, Drug Discovery World published our article on obstacles to innovation in pharma, which was informed by a great conversation on this blog in May.
Drug Discovery World wants to know and has asked the Pistoia Alliance to submit an article next month on this subject. And while we have some ideas already, we’d love to open this question to the floor. What do you see as the obstacles to innovation in the pharmaceutical industry?
The Pistoia Alliance was pleased to collaborate with the Innovative Medicines Initiative (IMI), Virtual Physiological Human (VPH) Network of Excellence, and Computational Modeling in Biology Network (COMBINE) communities to hold a biomedical data and model interoperability workshop on 28-29 March 2011.